EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study

Akifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, Taikan Hamomoto, Kazuki Kurosaka, Hideo Suzuki, Kenta Motomura

Anticancer Research · 2025

DOI: 10.21873/anticanres.17808 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Anticancer Research, 2025. Verfasst von Akifumi Kuwano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan; akuwnaoh1@aih-net.com. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Bevacizumab.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsQuinolinesBevacizumabPhenylurea CompoundsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleCost-Benefit AnalysisRetrospective StudiesAgedMiddle AgedNeoplasm StagingJapanTreatment OutcomeCost-Effectiveness Analysis

Stichwörter der Autor:innen

Hepatocellular carcinomaatezolizumab plus bevacizumabcost-effectivenessintermediate-stagelenvatinib

Substanzen

lenvatinibQuinolinesBevacizumabPhenylurea CompoundsAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan; akuwnaoh1@aih-net.com.
  • Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan.
  • Department of Gastroenterology, Ichinomiyanishi Hospital, Aichi, Japan.

Zitieren

APA

Kuwano, A., Yada, M., Tanaka, K., Hamomoto, T., Kurosaka, K., Suzuki, H., & Motomura, K. (2025). Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study. Anticancer Research. https://doi.org/10.21873/anticanres.17808

Vancouver

Kuwano A, Yada M, Tanaka K, Hamomoto T, Kurosaka K, Suzuki H, et al. Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study. Anticancer Research. 2025. doi:10.21873/anticanres.17808

BibTeX
@article{Kuwano2025,
  author = {Kuwano, Akifumi and Yada, Masayoshi and Tanaka, Kosuke and Hamomoto, Taikan and Kurosaka, Kazuki and Suzuki, Hideo and Motomura, Kenta},
  title = {Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17808}
}
Kostenlos starten →